Basiliximab
- Generic Name
- Basiliximab
- Brand Names
- Simulect
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 179045-86-4
- Unique Ingredient Identifier
- 9927MT646M
- Background
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.
- Indication
For prophylactic treatment of kidney transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Conditions
- Myelodysplastic SyndromeAcute Lymphoblastic LeukemiaSecondary Acute Myeloid LeukemiaAcute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: BasiliximabDrug: Fludarabine PhosphateDrug: Indium In 111-DOTA-BasiliximabDrug: MelphalanBiological: PaliferminRadiation: Total Lymphoid IrradiationRadiation: Total Marrow IrradiationBiological: Yttrium Y 90 Basiliximab
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT05139004
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.